Loading...
•
Dec 31, 2025
Scholar Rock Q4 2025 Earnings Report
Scholar Rock Q4 2025 Earnings Report
Key Takeaways
Scholar Rock reported a net loss of $91.0 million for the fourth quarter of 2025 as it prepares for the anticipated 2026 U.S. launch of apitegromab. The company secured a significant $550 million debt facility to support commercialization and is awaiting FDA reinspection of its fill-finish site to resubmit its BLA.
Apitegromab BLA resubmission and U.S. launch for SMA are anticipated in 2026 following constructive FDA meetings regarding the Catalent Indiana facility.
Secured a new debt facility of up to $550 million from Blue Owl Capital to support commercialization and pipeline advancement.
Cash, cash equivalents, and marketable securities stood at $367.6 million as of December 31, 2025.
European launch for apitegromab is expected in H2 2026, starting with Germany, pending EMA decision in mid-2026.
Forward Guidance
Scholar Rock is focused on the 2026 regulatory approval and commercial launch of apitegromab in the U.S. and Europe while advancing its clinical pipeline.
Positive Outlook
- Anticipated U.S. launch of apitegromab in 2026.
- EMA decision on MAA expected in mid-2026 with H2 2026 European launch.
- Access to up to $550 million in non-dilutive capital via new debt facility.
- Phase 2 FORGE trial for FSHD on track for initiation in mid-2026.
- Topline data for SRK-439 Phase 1 study expected in H2 2026.
Challenges Ahead
- BLA resubmission is dependent on successful FDA reinspection of a third-party facility (Catalent Indiana).
- Significant increase in G&A expenses due to commercial preparation.
- Ongoing net losses as the company remains in the pre-revenue stage.
- Technology transfer to a second fill-finish facility is still underway and requires a future sBLA.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...